Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors**
**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors**
Monoclonal ADC
#MonoclonalADC #Nectin4 #Solidtumor #9MW2821 #cervicalcancer #urothelialcarcinoma #esophagealcancer #breastcancer
Meet 9MW2821, a groundbreaking monoclonal antibody-drug conjugate (ADC) developed in China that targets Nectin-4, an adhesion molecule highly expressed in several solid tumors, including cervical cancer (CC), urothelial carcinoma (UC), esophageal cancer (EC), and breast cancer. Recently, this innovative therapy was granted Breakthrough Therapy Designation by the China Center for Drug Evaluation (CDE) for treating locally advanced or metastatic urothelial carcinoma, specifically in patients who have previously failed platinum-based chemotherapy and PD-(L)1 inhibitors.
The latest clinical results were unveiled at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the remarkable efficacy of 9MW2821 in a Phase 1/2 trial involving 260 patients with various advanced solid tumors. These included UC, triple-negative breast cancer (TNBC), EC, and CC. Among 37 evaluable UC patients, the disease control rate (DCR) soared to an impressive 91.9%, with an objective response rate (ORR) of 62.2%. Additionally, the median overall survival (mOS) reached 14.2 months, while the median progression-free survival (mPFS) was 8.8 months.
This promising therapy is poised to redefine treatment paradigms for patients with advanced solid tumors who have limited options, marking a significant milestone in the global oncology landscape.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp:+8613717959070
Email: doctor.huang@globecancer.com
#OncologyBreakthrough #CancerTreatment #Nectin4 #ADC #ClinicalResearch #Immunotherapy #UC #TNBC #CancerAwareness #BiotechInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Introducing the Momentum of the Next-Generation “Pan-Cancer” Targeted Therapy ICP-723 of China
Introducing the Momentum of the Next-Generation “Pan-Cancer” Targeted Therapy ICP-723 of China
Pan-Cancer
ICP-723
On April 11, 2022, InnoCare Pharma unveiled the preclinical data of ICP-723. The research results demonstrate that ICP-723 effectively inhibits the kinase activity of TRKA, TRKB, and TRKC (IC50 value less than 1 nM). Not only does ICP-723 exhibit potent in vitro efficacy in TRK-driven tumors, but it also overcomes resistance mutations commonly seen after treatment with first-generation TRK inhibitors, such as TRKA G595R and TRKC G623R/E.
TGI 89.5%
Further in vivo efficacy studies have confirmed the robust anti-tumor effect of ICP-723 in animal models. At a dosage of 1 mg/kg, ICP-723 achieves a tumor growth inhibition rate (TGI) of 89.5% in the KM12 tumor model. With high oral bioavailability, ICP-723 demonstrates overall favorable pharmacokinetic parameters.
Next-Generation NTRK Inhibitor
ICP-723, a Chinese developed next-generation NTRK inhibitor, holds promise in treating advanced or metastatic solid tumors harboring NTRK fusion genes, including breast cancer, colorectal cancer, lung cancer, thyroid cancer, and patients resistant to first-generation NTRK inhibitors like larotrectinib and entrectinib.
On August 31, 2021, InnoCare Pharma announced the Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate Phase I clinical trials of its second-generation pan-TRK inhibitor ICP-723 in the United States.
In the major financial performance report released by InnoCare Pharma in 2022, the efficacy of ICP-723 was also disclosed.
Objective Response Rate (ORR)
As of February 11, 2022, in the Phase I dose-escalation trial, 17 patients received treatment with ICP-723 at doses ranging from 1 to 8 mg once daily. The safety profile was favorable, with no dose-limiting toxicities (DLT) observed. Among the 17 patients, 5 were confirmed positive for NTRK gene fusion, with an objective response rate (ORR) of 80%, including partial responses in 4 cases, and a disease control rate (DCR) of 100%. In the 4 mg and above dose group, the objective response rate was 100%.
As a novel small molecule second-generation pan-TRK inhibitor, ICP-723 exhibits potent activity and high selectivity, offering the potential to overcome resistance to first-generation TRK inhibitors and better serve patients.
(Note: This clinical trial is still recruiting participants. Patients who have undergone genetic testing can review their reports. Once NTRK1/2/3 fusion is detected, they can immediately contact us Advanced Medicine in China )
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!
🌟✨ **Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!** ✨🌟
CAR-T Therapy
🔬 On January 2, 2024, a groundbreaking clinical study from China was published in *Nature*. This study, employing engineering design, enables CAR-T cells to secrete Interleukin-10 (IL-10), thereby enhancing metabolism within the tumor microenvironment. The modified IL-10 CAR-T cells increase oxidative phosphorylation in a mitochondrial acetoacetate carrier-dependent manner, resulting in complete regression of solid tumors and metastatic cancers, including colon cancer, breast cancer, melanoma, and pancreatic cancer. This breakthrough research offers new hope for cancer patients.
🌱 **The Miracle of IL-10** 🌱
The secretion of IL-10 promotes the proliferation and effector functions of CAR T cells, leading not only to the regression of solid tumors but also inducing stem cell-like memory responses in lymphoid organs, providing enduring protection against tumor re-attack. Specifically, IL-10 HER2 CAR-T cells achieved complete regression of MC38-HER2 tumors in mice, with a cure rate of 90%. In the case of melanoma, IL-10 TRP-1 CAR-T cells achieved a clearance rate of 60%, with significant success in treating the orthotopic B16F10 melanoma model.
🦠 **A Weapon against Relapse** 🦠
In addition to complete regression of solid tumors, IL-10 CAR-T cells demonstrated the ability to prevent relapse in immunodeficient mice. Mice treated with IL-10 CD19 hCAR-T cells for Raji or PANC1-CD19 tumors exhibited complete tumor regression without relapse, indicating stronger anti-tumor capabilities of IL-10 CAR-T cells in xenograft models. Particularly noteworthy is the effective elimination of pancreatic ductal adenocarcinoma (PDAC) tumors by IL-10 CD19 hCAR-T cells, resulting in complete response in all treated mice.
💊 **A Revolutionary Treatment Approach** 💊
These findings suggest that IL-10-expressing CAR-T cells are an effective immunotherapy against various solid tumors, capable of achieving complete regression in multiple synthetic and xenograft tumor models. What’s more exciting is that preliminary results indicate the metabolism-enhanced IL-10 CD19 CAR-T cell therapy developed by Leman Biotech requires extremely low treatment doses, consistently achieving complete remission in numerous relapsed/refractory lymphoma or leukemia patients, paving the way for a new era in cancer treatment.
✨ **A Beacon of Hope** ✨
This breakthrough study brings hope to cancer patients and demonstrates the immense potential of CAR-T therapy in cancer treatment. Looking ahead, further advancements in this technology promise to provide more opportunities for recovery and survival to patients worldwide. Let’s anticipate more breakthroughs together and strive towards conquering cancer
To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!#all #CARTtherapy #CancerTreatment #RRMM #IL10 #Tumor #Nature #MedicalBreakthrough #CARTCELL #coloncancer #breastcancer #melanoma #pancreatic 🌟🔬💊
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China Leading Global Advances in Breast Cancer Immunotherapy
🌟China Leading Global Advances in Breast Cancer Immunotherapy 🌟#ChinaInMedicine #BreastCancer
Breast Cancer
Since 2020, breast cancer has surpassed lung cancer, becoming the most common cancer globally with approximately 2.3 million new cases and 680,000 deaths annually. Despite improvements in traditional treatments like surgery, chemotherapy, and radiation, the mortality rate remains high. China’s Chimeric Antigen Receptor (CAR) immunotherapy is making significant strides, spearheading innovation in breast cancer treatment. 🇨🇳💪
China is not only a trailblazer in breast cancer immunotherapy research but also a miracle creator, bringing new hope to cancer patients worldwide. Let’s witness China’s outstanding achievements in the medical field and acknowledge its contribution to global health! 💊🌏
